Table 2. Summary of GPCR-modulating compounds that conferred retinal morphological and functional protection in bright light–exposed Abca4^−/−/Rdh8^−/− mice.

Morphological protection was assessed as morphological preservation of the retina by OCT imaging 7 days after exposure to bright light. Complete protection represented the retinas with intact ONL morphology similar to those of mice unexposed to bright light, with ONL thicknesses of ≥50 μm at 0.45 mm away from the optic nerve head (ONH) in the temporal retina. Functional protection was assessed by ERG analyses of retinal function in Abca4^−/−Rdh8^−/− mice 10 days after bright light exposure. Protection data were collected from at least five mice from each experimental group unless otherwise specifically indicated. ERG data are means ± SD, and statistical analyses were performed with either Student’s t test or analysis of variance (ANOVA). P < 0.05 was considered statistically significant.

Agent	Major action(s)	G protein category
SCH 23390 hydrochloride	Dopamine receptor D1 and D5 antagonist	Gs
Rotigotine hydrochloride	Dopamine receptor D2 and D3 agonist	Gi
2-Bromo-α-ergocryptine methanesulfonate salt	Dopamine receptor D2 and D3 agonist	Gi
Sumanirole maleate	Dopamine receptor D2 agonist	Gi
B-HT 920	Dopamine receptor D2, α2-adrenergic receptor agonist	Gi
Ro 10-5824 dihydrochloride	Dopamine receptor D4 agonist	Gi
YM 202074	mGluR1 receptor antagonist	Gq
Cinnabarinic acid	mGluR4 receptor agonist	Gi
Doxazosin*	Adrenergic receptor α1 antagonist	Gq
Tamsulosin*	Adrenergic receptor α1 antagonist	Gq
MTP tartrate	Adrenergic receptor β1 antagonist	Gs
ICI 118,551 hydrochloride	Adrenergic receptor β1 antagonist	Gs
GS 6201	Adenosine A2B receptor antagonist	Gs
PSB 1115	Adenosine A2B receptor antagonist	Gs
SC 19220	EP1 prostanoid receptor antagonist	Gq
CP 154526	Corticotropin-releasing factor 1 receptor antagonist	Gs
L-733060	Tachykinin NK1 receptor antagonist	Gq
CP 96345	Tachykinin NK1 receptor antagonist	Gq

^*Compounds identified from previous study (23).